A Controlled Trial of Renal Denervation for Resistant Hypertension (SYMPLICITY HTN-3)
Source: View publication →
In a rigorous sham-controlled trial, catheter-based renal-artery denervation failed to significantly reduce systolic blood pressure at 6 months compared to a sham procedure in patients with severe resistant hypertension.
Key Findings
Study Design
Study Limitations
Clinical Significance
SYMPLICITY HTN-3 profoundly impacted interventional cardiology by abruptly halting the widespread clinical adoption of renal denervation. By demonstrating that the dramatic blood pressure reductions observed in prior unblinded trials were largely attributable to placebo effects, medication compliance shifts, and regression to the mean, the trial proved the absolute necessity of rigorous sham controls in device trials involving subjective endpoints. It forced a total reset in the field, leading to the development of advanced multi-electrode catheters, stricter operator training, and rigorous biochemical drug-adherence testing in subsequent modern renal denervation trials (e.g., the SPYRAL HTN program).
Historical Context
Prior to 2014, earlier unblinded proof-of-concept and randomized trials (SYMPLICITY HTN-1 and HTN-2) reported astonishing drops in blood pressure (often exceeding 30 mm Hg) following renal sympathetic denervation. This fueled explosive enthusiasm and rapid CE mark approval in Europe, where thousands of patients were treated. The US FDA, however, mandated a rigorous, blinded, sham-controlled trial to confirm these benefits. When SYMPLICITY HTN-3 failed to meet its primary and secondary efficacy endpoints, it sent shockwaves through the medical community and device industry, serving as a landmark cautionary tale regarding the placebo effect in invasive interventions.
Guided Discussion
High-yield insights from every perspective
Based on the theoretical mechanism of renal denervation, which specific components of the autonomic nervous system are targeted, and how does their inhibition theoretically lower blood pressure?
Key Response
Renal denervation targets both sympathetic efferent and afferent nerves located in the adventitia of the renal artery. Efferent blockade is thought to reduce renin release, decrease sodium retention, and lower renal vascular resistance, while afferent blockade decreases central sympathetic tone. Understanding this highlights the physiologic rationale that drove the study despite the trial's ultimate negative clinical outcome.
A patient with resistant hypertension on three maximum-dose medications, including a diuretic, asks about renal denervation due to previous news coverage. How should you counsel them based on SYMPLICITY HTN-3, and what is the next best pharmacological step?
Key Response
Counseling should reflect that the sham-controlled SYMPLICITY HTN-3 showed no significant blood pressure reduction over a sham procedure, making it unrecommended for routine clinical use. The next step in management is optimizing medical therapy, ensuring adherence, ruling out secondary causes, and adding an aldosterone antagonist like spironolactone.
Subgroup analyses of SYMPLICITY HTN-3 suggested that certain procedural factors and patient demographics may have influenced the negative outcome. What were these key confounders, and how did they reshape subsequent renal denervation trial designs like SPYRAL HTN-OFF MED?
Key Response
Operator inexperience (many performed only 1-2 procedures), lack of intraprocedural confirmation of complete denervation, and significant changes in medication adherence confounded the results. Future trials mandated stricter adherence monitoring using drug assays, utilized better multi-electrode catheter designs, and included off-medication cohorts to isolate the pure procedural effect.
The striking discrepancy between the dramatic efficacy seen in earlier unblinded trials and the null results of SYMPLICITY HTN-3 served as a humbling moment in cardiology. What broad cognitive biases and methodological flaws in device trials does this highlight for evaluating future interventional technologies?
Key Response
It highlights the massive impact of the placebo effect, regression to the mean, observer bias, and the Hawthorne effect, where trial enrollment itself improves medication adherence. This trial cemented the absolute necessity of rigorous sham controls in procedural trials before widespread clinical adoption.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
SYMPLICITY HTN-3 faced severe criticism regarding treatment fidelity and intervention standardization. How could the trial design have integrated a biomarker or intraprocedural physiologic endpoint to validate the independent variable prior to assessing the primary clinical endpoint?
Key Response
The trial lacked a reliable, real-time measure of successful denervation, such as stimulated norepinephrine spillover reduction or intraprocedural changes in renal nerve stimulation. Without confirming successful manipulation of the independent variable, it is impossible to definitively differentiate a failure of the physiologic concept from a failure of the procedure's execution (Type III error).
Medication changes during the 6-month follow-up occurred frequently despite the protocol mandating stable regimens. As a reviewer, how does this post-randomization confounding threaten the internal validity of the trial, and what statistical methods could best adjust for this non-adherence?
Key Response
Frequent and unequal medication adjustments introduce time-varying confounding that distorts the true treatment effect, potentially masking a real benefit or creating a false negative. A reviewer would flag this as a critical threat to internal validity and demand sensitivity analyses using marginal structural models or inverse probability weighting to account for dynamic medication changes over time.
Following the publication of SYMPLICITY HTN-3, how should major hypertension guidelines classify the strength of recommendation for catheter-based renal denervation in resistant hypertension, and what evidence threshold is required to reconsider this in future updates?
Key Response
Major guidelines (like ACC/AHA) currently recommend against the routine use of renal denervation outside of clinical trials (Class III, Harm or No Benefit). To change this, guidelines require robust, reproducible data from newer-generation sham-controlled trials demonstrating sustained, clinically meaningful blood pressure reductions and long-term safety, alongside strict protocols ensuring medication adherence.
Clinical Landscape
Noteworthy Related Trials
SYMPLICITY HTN-2
Tested
Catheter-based radiofrequency renal denervation
Population
Patients with treatment-resistant hypertension
Comparator
Standard medical therapy
Endpoint
Change in seated office systolic blood pressure at 6 months
RADIANCE-HTN SOLO
Tested
Endovascular ultrasound renal denervation
Population
Patients with mild-to-moderate hypertension off medications
Comparator
Sham control procedure
Endpoint
Change in daytime ambulatory systolic blood pressure at 2 months
SPYRAL HTN-OFF MED
Tested
Radiofrequency renal denervation using a multi-electrode catheter
Population
Patients with uncontrolled hypertension off medications
Comparator
Sham control procedure
Endpoint
Change in 24-hour ambulatory systolic blood pressure at 3 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis